PR Newswire 科技新闻稿·· 4 小时前AI 评分58
Q32 Bio在EADV 2026公布bempikibart治疗斑秃SIGNAL-AA Part B结果
Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026
AI 导读
Q32 Bio在EADV 2026以late-breaker口头与海报形式公布bempikibart治疗重度或极重度斑秃的SIGNAL-AA Phase 2a Part B的36周结果及16周停药期初步数据。
来源：PR Newswire 科技新闻稿 · prnewswire.com